Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Angiogenesis inhibitors: current & future directions.

Shaker A Mousa1, Ahmed S Mousa

  • 1Albany College of Pharmacy & Pharmaceutical Research Institute (PRI) at Albany, 106 New Scotland Avenue, Albany, NY 12208-3492, USA. mousas@acp.edu

Current Pharmaceutical Design
|February 3, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RETRACTED: Sudha et al. Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol, a Thyrointegrin α<sub>v</sub>β<sub>3</sub> Antagonist as a Radio- and Chemo-Sensitizer in Pancreatic Cancer. <i>Biomedicines</i> 2022, <i>10</i>, 795.

Biomedicines·2025
Same author

RETRACTED: Godugu et al. Nanoformulated Ajwa (Phoenix Dactylifera) Bioactive Compounds Improve the Safety of Doxorubicin Without Compromising Its Anticancer Efficacy in Breast Cancer. <i>Molecules</i> 2020, <i>25</i>, 2597.

Molecules (Basel, Switzerland)·2025
Same author

RETRACTED: Block et al. Fluorinated Analogs of Organosulfur Compounds from Garlic (<i>Allium sativum</i>): Synthesis, Chemistry and Anti-Angiogenesis and Antithrombotic Studies. <i>Molecules</i> 2017, <i>22</i>, 2081.

Molecules (Basel, Switzerland)·2025
Same author

Editorial Expression of Concern: Nano-Targeted Delivery of Toremifene, an Estrogen Receptor-α Blocker in Prostate Cancer.

Pharmaceutical research·2025
Same author

Correction: Abou-ElNaga et al. Novel Nano-Therapeutic Approach Actively Targets Human Ovarian Cancer Stem Cells after Xenograft into Nude Mice. <i>Int. J. Mol. Sci</i>. 2017, <i>18</i>, 813.

International journal of molecular sciences·2025
Same author

RETRACTED: El-Far et al. Thymoquinone and Curcumin Defeat Aging-Associated Oxidative Alterations Induced by D-Galactose in Rats' Brain and Heart. <i>Int. J. Mol. Sci.</i> 2021, <i>22</i>, 6839.

International journal of molecular sciences·2024
Same journal

Role of Phenolic Nanocompounds in Inflammatory Disorders: Current View and Future Aspects.

Current pharmaceutical design·2026
Same journal

Overcoming Physiological Barriers in Brain Tumor Therapy: Advances in Nanomedicine, Ultramolecular Pharmaceuticals, and Targeted Drug Delivery.

Current pharmaceutical design·2026
Same journal

Breathing Life into Research: The Transformative Potential of Lung-on-a-Chip Technology.

Current pharmaceutical design·2026
Same journal

Cross-Tissue Transcriptome-Wide Association Study Prioritizes Candidate Genes and Compound-Associated Signatures for Osteoarthritis.

Current pharmaceutical design·2026
Same journal

Emerging Role of AI in Gastroenterology and Hepatology: Revolutionizing Medical Device-Assisted Diagnosis.

Current pharmaceutical design·2026
Same journal

Nanostructured Lipid Carriers in Drug Targeting: Characterization, Patents, and Recent Innovations.

Current pharmaceutical design·2026
See all related articles

Angiogenesis modulation shows promise in basic science but lacks clinical validation. Human patient models and hard endpoints are crucial for advancing therapies for diseases like diabetic retinopathy and macular degeneration.

Area of Science:

  • Focuses on the scientific principles and clinical applications of angiogenesis modulation.
  • Explores the discrepancy between experimental findings and clinical outcomes in angiogenesis research.

Background:

  • Basic science advancements in angiogenesis modulation are significant.
  • Clinical evidence supporting angiogenesis modulation strategies remains limited.
  • A gap exists between experimental data and clinical efficacy in human diseases.

Purpose of the Study:

  • To highlight the critical need for human-based models in studying angiogenesis-mediated disorders.
  • To emphasize the importance of clinical outcome measures, including benefit/risk, hard endpoints, and cost-effectiveness.
  • To redefine the role of experimental models in guiding clinical angiogenesis research.

Main Methods:

  • Utilizes human cancer patients as models for malignancy.

Related Experiment Videos

  • Employs human patients with diabetic retinopathy (DR) and age-related macular degeneration (AMD) for ocular angiogenesis studies.
  • Advocates for incorporating benefit/risk ratios, mortality, quality of life, and cost-effectiveness in clinical evaluations.

    • Main Results:

    • Experimental models are best suited for mechanistic understanding and guidance, not predicting clinical efficacy.
    • Human patient data is essential for validating angiogenesis modulation strategies.
    • Numerous angiogenesis modulation strategies have been identified, targeting various biological systems.

    Conclusions:

    • Human patient-derived data and clinically relevant endpoints are paramount for successful angiogenesis modulation therapies.
    • Experimental models should complement, not replace, human studies.
    • Future strategies must integrate with existing treatments to improve efficacy and safety.